PRICED Act
USA116th CongressHR-3379| House
| Updated: 6/21/2019
Janice D. Schakowsky
Democratic Representative
Illinois
Cosponsors (22)
Marcy Kaptur (Democratic)Barbara Lee (Democratic)Mark Pocan (Democratic)David N. Cicilline (Democratic)Bobby L. Rush (Democratic)Andy Levin (Democratic)Angie Craig (Democratic)Rosa L. DeLauro (Democratic)Ro Khanna (Democratic)Joseph D. Morelle (Democratic)Raja Krishnamoorthi (Democratic)Bruce Westerman (Republican)Pramila Jayapal (Democratic)Eleanor Holmes Norton (Democratic)Jamie Raskin (Democratic)Alexandria Ocasio-Cortez (Democratic)Peter Welch (Democratic)Jesús G. "Chuy" García (Democratic)Grace Meng (Democratic)Rashida Tlaib (Democratic)Lloyd Doggett (Democratic)Judy Chu (Democratic)
Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period. This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Health
Drug safety, medical device, and laboratory regulationLicensing and registrationsMarketing and advertising
PRICED Act
USA116th CongressHR-3379| House
| Updated: 6/21/2019
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period. This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Janice D. Schakowsky
Democratic Representative
Illinois
Cosponsors (22)
Marcy Kaptur (Democratic)Barbara Lee (Democratic)Mark Pocan (Democratic)David N. Cicilline (Democratic)Bobby L. Rush (Democratic)Andy Levin (Democratic)Angie Craig (Democratic)Rosa L. DeLauro (Democratic)Ro Khanna (Democratic)Joseph D. Morelle (Democratic)Raja Krishnamoorthi (Democratic)Bruce Westerman (Republican)Pramila Jayapal (Democratic)Eleanor Holmes Norton (Democratic)Jamie Raskin (Democratic)Alexandria Ocasio-Cortez (Democratic)Peter Welch (Democratic)Jesús G. "Chuy" García (Democratic)Grace Meng (Democratic)Rashida Tlaib (Democratic)Lloyd Doggett (Democratic)Judy Chu (Democratic)
Health Subcommittee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Drug safety, medical device, and laboratory regulationLicensing and registrationsMarketing and advertising